Clinical StudyPercutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma
Section snippets
MATERIALS AND METHODS
An institutional review board–approved retrospective analysis was performed on all patients with pancreatic adenocarcinoma treated with percutaneous IRE at a single institution. The primary objective of this analysis was to evaluate the safety and feasibility of this modality for pancreatic tumors. Secondary objectives were to determine the response to treatment and survival after the procedure. Data were collected on baseline characteristics for all patients treated, and all pre- and
RESULTS
Between December 2010 and February 2012, 14 patients with pancreatic adenocarcinoma underwent IRE procedures at our institution. One patient with LAPC who underwent IRE had local progression of disease after 7 months and was treated again with IRE. Therefore, a total of 15 percutaneous IRE procedures were performed on 14 patients. Table 1 shows the baseline pretreatment characteristics of the treated patients. Twelve of these 15 cases had disease localized to the pancreas, and the remaining
DISCUSSION
IRE is a relatively new nonthermal modality for ablation of soft-tissue tumors. Since the technology became available at our institution, it has been used for percutaneous ablation of soft-tissue tumors as well as on an off-label basis in organs such as the liver, lungs, kidneys, and prostate (27). After acquiring experience in the technique, we began using IRE percutaneously to ablate pancreatic tumors. To our knowledge, our experience is the largest series of patients treated with
Acknowledgments
The authors thank Monica T. Garcia-Buitrago, MD, Associate Professor Clinical Pathology, University of Miami Miller School of Medicine and Jackson Memorial Hospital.
References (29)
- et al.
Radiofrequency ablation in pancreatic cancer
HPB (Oxford)
(2006) - et al.
Irreversible electroporation is a surgical ablation technique that enhances gene transfer
Surgery
(2011) - et al.
Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models
Cancer Lett
(2012) - et al.
Irreversible electroporation of the pancreas in swine: a pilot study
HPB (Oxford)
(2010) - et al.
Investigation of the safety of irreversible electroporation in humans
J Vasc Interv Radiol
(2011) - et al.
Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report
J Vasc Interv Radiol
(2012) - et al.
Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma
J Am Coll Surg
(2012) Cancer Facts & Figures 2011
(2011)- et al.
Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement
Ann Surg Oncol
(2009) - et al.
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages
PLoS Med
(2010)
National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
J Clin Oncol
Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
N Engl J Med
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial
J Clin Oncol
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
J Clin Oncol
Cited by (194)
Irreversible electroporation and electrochemotherapy in oncology: State of the art
2022, Diagnostic and Interventional ImagingIrreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues
2024, Medicina (Lithuania)
From the SIR 2012 Annual Meeting.
G.N. is a consultant for AngioDynamics (Queensbury, New York), the manufacturer of the NanoKnife. None of the other authors have identified a conflict of interest.